The OCULAB program seeks to make diagnosis, monitoring, and treating ocular and systemic conditions like dry eye disease more precise, more efficient, and less invasive for patients. The program will build on advancements in continuous monitoring biosensor technologies, sustained-release ocular drug devices, and AI algorithms for therapeutic delivery to alleviate the burden of patient medication compliance, improve data collection for ocular and systemic disease, and ultimately improve patient outcomes. The OCULAB platform consists of two (2) primary components: a biosensor to continuously monitor tear biomarkers which must fit in the form factor of a punctal plug or comparable tear duct insert, and a disease-modifying therapeutic which will be automatically delivered via an AI-enabled closed-loop system from the same housing as the biosensor or from a separate periocular implant. By utilizing validated disease biomarkers present in tears and employing AI algorithms to drive closed-loop delivery of a therapeutic, OCULAB has the potential to become the first in situ tear biomarker measurement system, the first continuous monitor of multiple systemic chemistry biomarkers, and the first AI-powered closed loop ultra-precise medication delivery system.
Deadlines:
o Solution Summary: January 27, 2025
o Proposal Due Date: April 14, 2025
TA1: Continuously-monitoring nanosensor
TA2: Closed-Loop Therapeutic Dosing